DK1158989T3 - Anvendelse af inhibitorer af endotoksin til behandling af kakeksi - Google Patents

Anvendelse af inhibitorer af endotoksin til behandling af kakeksi

Info

Publication number
DK1158989T3
DK1158989T3 DK00916915T DK00916915T DK1158989T3 DK 1158989 T3 DK1158989 T3 DK 1158989T3 DK 00916915 T DK00916915 T DK 00916915T DK 00916915 T DK00916915 T DK 00916915T DK 1158989 T3 DK1158989 T3 DK 1158989T3
Authority
DK
Denmark
Prior art keywords
lps
endotoxin
lipopolysaccharide
gut
patient
Prior art date
Application number
DK00916915T
Other languages
English (en)
Inventor
Hans-Dieter Volk
Mathias Plauth
Herbert Lochs
Original Assignee
Anker Stefan
Volk Hans Dieter
Schumann Ralf Reiner
Coats Andrew
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9905310.0A external-priority patent/GB9905310D0/en
Priority claimed from GBGB9905315.9A external-priority patent/GB9905315D0/en
Priority claimed from GBGB9905307.6A external-priority patent/GB9905307D0/en
Priority claimed from GBGB9905314.2A external-priority patent/GB9905314D0/en
Priority claimed from GBGB9905300.1A external-priority patent/GB9905300D0/en
Application filed by Anker Stefan, Volk Hans Dieter, Schumann Ralf Reiner, Coats Andrew filed Critical Anker Stefan
Application granted granted Critical
Publication of DK1158989T3 publication Critical patent/DK1158989T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
DK00916915T 1999-03-09 2000-03-09 Anvendelse af inhibitorer af endotoksin til behandling af kakeksi DK1158989T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9905310.0A GB9905310D0 (en) 1999-03-09 1999-03-09 Therapy and use of compounds in therapy (4)
GBGB9905315.9A GB9905315D0 (en) 1999-03-09 1999-03-09 Therapy and use of compounds in therapy
GBGB9905307.6A GB9905307D0 (en) 1999-03-09 1999-03-09 Therapy and use of compounds in therapy
GBGB9905314.2A GB9905314D0 (en) 1999-03-09 1999-03-09 Therapy and use of compounds in therapy (2)
GBGB9905300.1A GB9905300D0 (en) 1999-03-09 1999-03-09 Therapy and use of agents in therapy
PCT/EP2000/002062 WO2000053165A2 (en) 1999-03-09 2000-03-09 Use of inhibitors of endotoxin for the treatment of chachexia

Publications (1)

Publication Number Publication Date
DK1158989T3 true DK1158989T3 (da) 2007-10-22

Family

ID=27517498

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00916915T DK1158989T3 (da) 1999-03-09 2000-03-09 Anvendelse af inhibitorer af endotoksin til behandling af kakeksi

Country Status (10)

Country Link
US (2) US20070197485A1 (da)
EP (2) EP1212064A2 (da)
AT (1) ATE365043T1 (da)
AU (2) AU3809900A (da)
CY (1) CY1107436T1 (da)
DE (1) DE60035262T2 (da)
DK (1) DK1158989T3 (da)
ES (1) ES2288847T3 (da)
PT (1) PT1158989E (da)
WO (2) WO2000053165A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1302206A1 (en) * 2001-10-11 2003-04-16 Universitair Medisch Centrum Utrecht Methods and means for the use of the adventitial toll-like receptor
US20040122067A1 (en) * 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
WO2004082578A2 (en) * 2003-03-21 2004-09-30 Mellitus S.L. Use of soluble cd14 for treatment of diseases
US7883701B2 (en) * 2003-12-19 2011-02-08 Wisconsin Alumni Research Foundation Method for enhancing growth or increasing feed efficiency through reducing binding between endotoxin and its receptor in the gastrointestinal tract
JPWO2005117920A1 (ja) * 2004-06-02 2008-04-03 株式会社クレハ 循環器機能障害因子除去剤
AR051836A1 (es) 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
EP1741440A1 (en) * 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
ES2435775T3 (es) 2005-10-27 2013-12-23 Janssen Biotech, Inc. Moduladores de receptor tipo Toll 3, procedimientos y usos
KR100785656B1 (ko) * 2007-05-14 2007-12-17 재단법인서울대학교산학협력재단 소염제로 사용되는 소디움글리코콜레이트 또는 그 유도체
EP2208497A1 (en) * 2009-01-15 2010-07-21 Charité-Universitätsmedizin Berlin (Charité) Use of Ursodeoxycholic acid (UDCA) for enhancing the general health condition of a tumor patient
CN115120681A (zh) * 2022-07-19 2022-09-30 浙江长三角聚农科技开发有限公司 竹笋生物炭在制备治疗糖尿病及其并发症药物中的应用
CN115137733B (zh) * 2022-08-24 2024-01-02 吉林大学 熊去氧胆酸在制备mcr-3酶抑制剂中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377595A (en) * 1979-08-13 1983-03-22 Massachusetts Institute Of Technology Process for reducing depression
US4898879A (en) * 1981-06-29 1990-02-06 Baxter International Inc. Nurtitional composition for management of hepatic failure
US5087453A (en) * 1990-11-01 1992-02-11 Otsuka Pharmaceutical Co., Ltd. Method for the treatment of bacterial caused weight loss and/or hypoglycemia
US5674855A (en) * 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
US5589358A (en) * 1993-12-29 1996-12-31 Univ Wake Forest Ileal bile acid transporter compositions and methods
IT1274000B (it) * 1994-04-06 1997-07-14 Alfa Wassermann Spa Derivati di acidi biliari utili nella terapia della calcolosi biliare da colesterolo e nelle patologie indotte da colestasi
US5763435A (en) * 1995-11-21 1998-06-09 Children's Hospital Medical Center Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue

Also Published As

Publication number Publication date
EP1212064A2 (en) 2002-06-12
EP1158989A2 (en) 2001-12-05
WO2000053165A3 (en) 2001-04-12
ATE365043T1 (de) 2007-07-15
CY1107436T1 (el) 2012-12-19
ES2288847T3 (es) 2008-02-01
PT1158989E (pt) 2007-10-01
DE60035262T2 (de) 2008-02-21
EP1158989B1 (en) 2007-06-20
US20070197485A1 (en) 2007-08-23
AU3809900A (en) 2000-09-28
US20090197851A1 (en) 2009-08-06
DE60035262D1 (de) 2007-08-02
AU4105600A (en) 2000-09-28
WO2000053165A2 (en) 2000-09-14
WO2000053224A2 (en) 2000-09-14
WO2000053224A3 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
CY1107436T1 (el) Χρηση των αναστολεων της ενδοτοξινης για την θεραπεια της καχεξιας
Wersall et al. Ototoxicity of gentamicin
Bagby et al. Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis
Johnson et al. Effects of fat, secretin, and cholecystokinin on histamine-stimulated gastric secretion
CN102791262A (zh) 用于处理生物薄膜的d-氨基酸
ATE247974T1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
Jiang et al. Monitoring of serum markers for fibrosis during CCl4-induced liver damage: Effects of anti-fibrotic agents
SE9800550D0 (sv) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
DE69410254T2 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
Scott et al. Adjuvant activity of saponin: antigen localization studies
Lu et al. Hydrogen sulfide alleviates peritoneal fibrosis via attenuating inflammation and TGF-β1 synthesis
RU95112534A (ru) Дерматансульфаты и их соли, противотромбозные средства, способ предупреждения или лечения тромбозов, способ предупреждения или лечения синдрома рассеянной интраваскулярной коагуляции, способ лечения инфаркта миокарда
WO2002020619A3 (en) HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
DE69733557D1 (de) Endothelin-antagonisten zur behandlung von herzversagen
Nagao et al. Immunotherapy for the treatment of acute paraquat poisoning
Trooskin et al. Failure of demonstrated clinical efficacy of antibiotic-bonded continuous ambulatory peritoneal dialysis (CAPD) catheters
EA200501057A1 (ru) Фармацевтическая комбинация для профилактики или терапевтического лечения сердечно-сосудистых, сердечно-легочных, легочных или почечных заболеваний
US6753341B1 (en) Inhibition of PKC to treat permability failure
MA31719B1 (fr) Procede pour pratiquer une intervention coronaire percutanee
Bennett et al. Effect of angiotensin-converting enzyme inhibitors on resistance artery structure and endothelium-dependent relaxation in two-kidney, one-clip Goldblatt hypertensive and sham-operated rats
PT1156795E (pt) Utilizacao de acido succinico ou de seus sais e metodo de tratamento da resistencia a insulina
Carlson et al. Glomerular localization of circulating single-stranded DNA in mice. Dependence on the molecular weight of DNA
Cave Helicobacter pylori and its interaction with chief and parietal cells.
El Munshid et al. Importance of the kidneys for gastrin elimination and gastric function